Thx. Paul. You touched on the question I had. Without knowing what the "competitors" are doing, is EvH's NGIO vaccine alone in that it is synthetic? Haven't we been told that the synthetic nature of AE 37 will allow quicker and broader production?

I have listened to as much of the Remdesivir discussion as possible, and I am invested in Cytodyn, and it sounds like their production will be limited initially, even if they come on line. For this reason does NGIO have an advantage in acquiring funding and administering the vaccine if it is approved?